COVID-19 has bought significant change in the digital PCR market. The demand for the dPCR increased over the years owing to sensitivity to detecting extremely low viral load samples.
Digital PCR (dPCR) can detect the tiniest traces of RNA and DNA that are not usually detected by the conventional PCR systems. The device helps to diagnose infectious diseases caused by viruses, bacteria, and cancer mutations. Hence, there was a growing demand for the digital PCR systems across the globe. To its growing importance, diagnostic companies are also actively involved in development of new digital PCR products.
On 22nd August 2022, Roche has launched its Digital LightCycler System, a digital PCR system, it will help to understand the patient’s cancer, genetic disease, and infections. The Digital LightCycler System is the Roche’s first digital Polymerase Chain Reaction Device. It is going to be available in 15 countries in 2022.
The launch of digital PCR will complement the Roche molecular diagnostics division which is growing at rapid pace from COVID-19. The device will help them to gain more market share in the molecular testing laboratories.
Qiagen is improvising its applications for QIAcuity by collaborating with various companies. The ultrasensitive digital PCR (dPCR) platform can process the samples in two hours rather than the five hours compared with the other devices.
On 27th July 2022, Qiagen enhanced its QIAcuity series for biopharmaceutical users. The enhancement will allow the quantification of AAV viral titer and residual host cell DNA in cell and gene therapy. The company launched the custom design assay service, allowing users to carry out custom multiplex assays beyond biopharma applications.
On 1st June 2022, USA CDC endorsed using Qiagen’s QIAcuity digital PCR system for wastewater surveillance of 30 pathogens, including the COVID-19 virus.